Wednesday, 17 Oct 2018

PsA/SpA

Datesort ascending Type Title Save
05 Jan 2018 Social Check out Dr. Artie Kavanaughs #ACR17 video review of new PsA treatments and outcome measures from ACR17 meeting. https://t.co/TgfVFDTh1i
02 Jan 2018 News MEASURE 3 Study - Anti-IL17 Benefits Persist in Spine Disease
30 Dec 2017 Social RT @ARD_BMJ: Inequity in biological DMARDs uptake for #spondyloarthritis across the globe: results from the ASAS-COMOSPA study https://t.co…
29 Dec 2017 Social Causes of Dactylitis = PsA, AS, SpA, reactive arthritis, MCTD, PSS, TB, syphilis, JIA, Sarcoid https://t.co/nhotKuYF2n
28 Dec 2017 News Therapeutic Update: 5 Questions on FDA Hearing for Tofacitinib in PsA (Best of 2017)
26 Dec 2017 Social FDA approves Xeljanz (tofacitinib) for use in adults with psoriatic arthritis, alone or in combo w/ MTX/DMARDs. But warns agains combining with biologics, cyclosporine or azathioprine as these have not been studied. https://t.co/MWgIp8uuUw
22 Dec 2017 Social 320 kids with juvenile PsA from CARRA shows 1 in 5 w/ JPsA are obese and > one-third were overweight. https://t.co/cZE0cHl68g
22 Dec 2017 Social SPIRIT-P1 study of Taltz (IXE) in PsA shows that after initial 24 blind, PBO & ADA pts rerandomized to IXE q2 or q4 wks==ACR20/50/70 of 69%/55%/39% for q2wk and 69%/53%/40% for q4wk at 1 yr. https://t.co/IPg1Hf7VoT
21 Dec 2017 Social Swedish analysis of 38,702 AS/SpA/PsA pts (vs 200,417 gen population) shows Biological-naïve AS/PsA /SpA have no incr risk of TB risk (OR 1.2; 0.5 to 2.7); but biologic use incr risk of TB (OR 7.5) https://t.co/zqPpxLZk5q
21 Dec 2017 Social 320 kids with juvenile PsA from CARRA shows 1 in 5 w/ JPsA are obese and > one-third were overweight. https://t.co/MoMW3Hpvqu
21 Dec 2017 News Cardiac Disturbances Increased in Spondyloarthritis
21 Dec 2017 Social Check out #ACR17 Video by Dr. Julio Gonzales-Paoli on highlight PsA and SpA presentations at ACR https://t.co/MoYzRpJdMb
21 Dec 2017 Social Metanalysis of 7 RCTs on IL-17 inhibitors in PsA shows a 2 fold greater ACR20 response, with no increased risk of infection, AE, TB, candida or SAE https://t.co/rrBD3Wokqt
18 Dec 2017 ACR Video Dr. Philip Mease: Risankizumab in Psoriatic Arthritis (Abstract 2L)
17 Dec 2017 Social FDA approves Xeljanz (tofacitinib) for use in adults with psoriatic arthritis, alone or in combo w/ MTX/DMARDs. But warns agains combining with biologics, cyclosporine or azathioprine as these have not been studied. https://t.co/ffsAfiaU70
16 Dec 2017 Social RT @DrPetryna: Delay in PSA Dx by >6 mo significantly increases risk of functional disability and structural damage #NYU 3rd annual seminar…
16 Dec 2017 Social RT @DrPetryna: Can effective treatment of psoriasis prevent onset of PSA? Prevention trial on the drawing board #psoriaticarthritis #preven…
15 Dec 2017 News FDA Approves Xeljanz for Use in Psoriatic Arthritis
11 Dec 2017 News 2017 Update of Treat to Target Recommendations for SpA/PsA
04 Dec 2017 News Ixekizumab (Taltz) FDA Approved for Psoriatic Arthritis